Chapter 6: Radiobiology

NPRE441:Principles of Radiation Protection Spring 2023, MW 12-1.50 pm 2018

Campus Instructional Facility

Co-Instructor: Dr. Kim A. Selting DVM, MS, DACVIM (Oncology), DACVR (Radiation Oncology) Associate Professor, Veterinary Clinical Medicine <u>seltingk@Illinois.edu</u>

Objective:

To familiarize the students with the basic principles of radiobiology.



Ministry of the Environment Government of Japan Slides retrieved and adapted from:

- Slide deck NPRE441 Spring 2023 by Dr. Elena Zannoni
- Slide deck NPRE441 Spring 2021 by Prof.L.J. Meng (UIUC, USA)
- slide deck prepared in 2006 by Dr.E.B.
 Podgorsak (McGill University, Montreal)
- slide deck prepared in 2015 by Dr.M. Cremonesi (IEO European Institute of Oncology, Milano, Italy)
 slide deck prepared by Dr.E.Okuno (Institute of Physics of S. Paulo University, S. Paulo, Brazil)

CHAPTER 6. TABLE OF CONTENTS PART 4

1. Cell survival curves

- A. linear-quadratic model
- B. single-hit single-target model
- C. multi-target-single hit model
- D. The α/β ratio
- 2. Dose response curves
- 3. Normal and tumor cells: Therapeutic ratio
- 4. Relative biological effectiveness (RBE)
- 5. Oxygen effect
- 6. Dose rate and fractionation
- 7. Radioprotectors and radiosensitizers



CHAPTER 6. TABLE OF CONTENTS PART 4

1. Cell survival curves

- A. linear-quadratic model
- B. single-hit single-target model
- C. multi-target-single hit model
- D. The α/β ratio
- 2. Dose response curves
- 3. Normal and tumor cells: Therapeutic ratio
- 4. Relative biological effectiveness (RBE)
- 5. Oxygen effect
- 6. Dose rate and fractionation
- 7. Radioprotectors and radiosensitizers



Effect of fractionation - concepts

- Conventionally fractionated (15-30 doses)
- Hypofractionated
 - Controversy about the use of LQ model
- Hyperfractionated
- Stereotactic Ablative Radiotherapy (SABR) 1-5 doses over ~1 week
- Accelerated repopulation
- Dose rate effect
 - Ultralow mGy/hr
 - Low <1 Gy/min
 - Standard 6 Gy/min
 - High (flattening filter free) 14 Gy/min
 - Ultra High Dose Rate (FLASH effect) >40 Gy/sec



- Cell survival curve (surviving fraction against absorbed dose) describes the relationship between:
 - Surviving fraction of cells, i.e., the fraction of irradiated cells that maintain their reproductive integrity (clonogenic cells)
 - Absorbed dose.
- Cell survival against dose is graphically represented by plotting the surviving fraction S(D) on a logarithmic scale on the ordinate against dose D on a linear scale on the abscissa.



Radiation dose (Gy)



Typical survival curves for cells irradiated by densely ionizing radiation (high LET) and sparsely ionizing radiation (low LET)

For high LET radiation, the survival curve may be exponential, i.e. linear on a semi-logarithmic plot





Type of radiation influences the shape of the survival curve.

- For densely ionizing radiation (high LET) the cell survival curve is almost an <u>exponential function of dose</u> (shown by an almost straight line on a log-linear plot).
- For sparsely ionizing radiation (low LET) the survival curves show an initial slope followed by a <u>shoulder region</u> and then become nearly straight at high doses.
- Many mathematical models of varying degrees of complexity have been developed to describe the shape of the cell survival curve.





1. Linear-quadratic (LQ) model

- The most common model used today is the *linear-quadratic model*, where cell death as a function of dose is described by a second-order polynomial
- This model assumes that there are two components to cell killing by radiation, commonly represented by two constants, α and β
- In this model, cell survival fraction *S* is described as a function of dose *D* by the following equation:

$$S = e^{-(\alpha D + \beta D^2)}$$



- α is a constant describing the initial slope of the cell survival curve.
- β describes the quadratic component.



1. Linear-quadratic (LQ) model

- A plausible explanation of the **linear component** is that the majority of DNA-interactions are singleradiation track events
- Under these circumstances, DNA damage can be effectively repaired before possible interaction with another single track when enough time is available and doses are relatively low
- As the dose or dose rate increases, multi-track events, reflecting the quadratic component, will predominate resulting in an increased probability of mis-repair and cell death
- Over 90% of radiation oncologists use the LQ model



• Ratio α/β gives the dose at which the linear and quadratic components of cell killing are equal.



Sub-lethal (or accumulated) damage results from accumulation of events that individually are incapable of killing a cell but that together can be lethal





1. Linear-quadratic (LQ) model

α component

- Linear variation with dose (Gy⁻¹)
- Lethal : one hit = one sterile cell
- DSB

β component

- Quadratic variation with dose (Gy-2)
- Some damage repaired, some not
- SSB (multiple)

 α/β number (ratio) is defined by the dose at which the two contribute equally to the survival curve

α/β ratio high (>10)



Curve linear at origin
Early responding normal tissues
Fast growing tumor



α/β ratio low (~3)

Curve with shoulder at the beginning
Late responding normal tissues
Tumor with high repair capability

With regard to response time two types of tissue are known:

□ HIERARCHICAL OR EARLY-RESPONDING TISSUES

- Rich in stem cells and highly proliferative progenitor cells that differentiate into functional differentiated cells.
- They have a high turnover rate and a high rate of cell loss.
- They **respond rapidly to irradiation** and fail when the precursor pool fails to generate enough differentiated cells.
- Examples are Gut, Skin, Bone Marrow, Mucosa and most TUMORS

□ FLEXIBLE OR SLOW-RESPONDING TISSUES

- Tissues with a **slow turnover rate** and **respond slowly to irradiation**.
- They fail when there is enough irreparable damage to lead to cell death, generally after a **long lag period**.
- Examples are Brain, Spinal Cord, Kidney, Lung, Bladder



1. Linear-quadratic (LQ) model

Early-Responding Tissues	α/β	Late-Responding Tissues	$lpha/eta^{b}$
Jejunal mucosa	13	Spinal cord (110,166,245,284,285,322)	1.6–5
Colonic mucosa	7	Kidney (44,127,291,305)	0.5-5
Skin epithelium	10	Lung (90,211,214,275,289,295)	1.6-4.5
Spermatogenic cells	13	Liver (91)	1.4-3.5
Bone marrow	9	Human skin (32,211,279,280)	1.6-4.5
Melanocytes (302)	6.5	Cartilage and submucosa (171.329)	1.0-4.9
Tumors		(
Mouse fibrosarcoma metastases (173) Human tumors (169,171,195,258) Experimental tumors (306)	10 6–25 10–35	Dermis (106) Bladder (252,265) Bone (212)	2.5 ± 1.0 5.0-10.0 1.8-2.5

• The LQ model best describes data in the range of 1 - 6Gy and it is debated whether it can be used outside this range



2. Single-hit single-target model

An alternative older model is the **single-hit single-target model** described by:

$$S = e^{-D/D_0}$$

 D_0 is effectively the reciprocal of α (of LQ model) and **represents the dose which reduces survival** to *e* ⁻¹ or 37 %

The target theory is based upon the idea that there are *n* targets in a cell, all of which must be "hit" to kill the cell

Extrapolation number n (the point of intersection of the slope on the log survival axis).





3. Single-hit multi-target model

 The log-linear relationship is consistent with data from some bacteria (procaryotes) but it does not apply in eukaryotic cells (except at high LET), which show <u>shouldered survival curves</u> that can be accommodated by a *single-hit multi-target model* described by:

$$S = 1 - (1 - e^{-D/D_0})^n$$

n is the number of targets

 This is reliable at high dose but not at low dose, because it does not describe accurately the 'shoulder' region at low doses





CHAPTER 6. TABLE OF CONTENTS PART 4

1. Cell survival curves

- A. linear-quadratic model
- B. single-hit single-target model
- C. multi-target-single hit model
- D. The α/β ratio

2. Dose response curves

- 3. Normal and tumor cells: Therapeutic ratio
- 4. Relative biological effectiveness (RBE)
- 5. Oxygen effect
- 6. Dose rate and fractionation
- 7. Radioprotectors and radiosensitizers



6.4.2 DOSE RESPONSE CURVES

- Plot of a biological effect observed (e.g., tumor induction or tissue response) against the dose given is called a dose response curve.
- Generally, **as the dose increases so does the effect.**
- Three types of dose response relationships are known:
 - Linear
 - Linear-quadratic
 - Sigmoid
- Threshold dose is the largest dose for a particular effect studied below which no such effect is observed.





6.4.2 DOSE RESPONSE CURVES



Dose response curves

- (A) Linear relationship with no threshold.
- (B) Linear relationship with threshold.
- (C) Linear-quadratic relationship with no threshold (**stochastic effects** such as carcinogenesis).
- (D) Linear relationship with no threshold and the area under the dashed line representing the natural incidence of the effect.
- (E) Sigmoid relationship with threshold D1, as is common for deterministic effects in tissues.



Deterministic Effects and Stochastic Effects

Deterministic effects

(Hair loss, cataract, skin injury, etc.)

When a number of people were exposed to the same dose of radiation and certain symptoms appear in 1% of them, said dose is considered to be the threshold dose.

(2007 Recommendations of the International Commission on Radiological Protection (ICRP))



Stochastic effects

(Solid cancer, leukemia, hereditary effects)

Effects of radiation exposure under certain doses are not clear because effects of other cancer-promoting factors such as smoking and drinking habits are too large. However, the ICRP specifies the standards for radiological protection for such low-dose exposures, assuming that they may have some effects as well.



CHAPTER 6. TABLE OF CONTENTS PART 4

- 1. Cell survival curves
 - A. linear-quadratic model
 - B. single-hit single-target model
 - C. multi-target-single hit model
 - D. The α/β ratio
- 2. Dose response curves
- 3. Normal and tumor cells: Therapeutic ratio
- 4. Relative biological effectiveness (RBE)
- 5. Oxygen effect
- 6. Dose rate and fractionation
- 7. Radioprotectors and radiosensitizers



- Cancer is characterized by a disorderly proliferation of cells that can invade adjacent tissues and spread via the lymphatic system or blood vessels to other parts of the body.
- Aim of radiotherapy is to deliver enough radiation to the tumor to destroy it without irradiating normal tissue to a dose that will lead to serious complications (morbidity).
- It is imperative that the doses to normal tissues be kept lower than the doses to tumors in order to:
 - Minimize treatment complications.
 - Optimize treatment outcomes.

- Principle of radiotherapy is usually illustrated by plotting two sigmoid curves:
 - For tumor control probability (TCP).
 - For normal tissue complication probability (NTCP).



- Optimal choice of radiation dose delivery technique in treatment of a given tumour is such that it maximizes the TCP and simultaneously minimizes the NTCP.
- For a typical good radiotherapy treatment:

• TCP
$$\geq 0.5$$

• NTCP ≥ 0.05



- Different tissues have different tolerances to irradiation and fail at different times after irradiation (intrinsic radiosensitivity)
- LATENCY: Different tissues take different times to express damage. This depends on their cell turnover time. →
 It is NOT an indicator of radiosensitivity.
- There is no relationship between latency and tolerance
- E.g. After moderate doses, gut fails first, then bone marrow, then lung, but the hematopoietic system is the most radiosensitive



Tumor Control Probability (TCP)

In order to cure a tumor, **the last surviving clonogen must be killed** → it is a probability function of dose.

 $TCP = e^{-x} = e^{-(m^*S)} = e^{-m^*e^{-(\alpha D + \beta D^2)}} \text{ or } e^{-(m^*e^{-(D/D0)})}$

where **x** is the number of surviving clonogenic stem cells **m** is the initial number of clonogens

If there is an average of 1 cell surviving TCP=37%



- Several factors can alter radiosensitivity and widen or narrow the therapeutic ratio:
 - Oxygenation status → hypoxia (resistance) or normoxia (sensitivity).
 - Addition of radioprotectors (free radical scavengers, Amifostine – thiol donor)
 - Addition of radiosensitizers (chemotherapy, others)
 - Use of low dose rates or multi-fractionated irradiation.
 - Synchronization of cells in the late S phase of the cell cycle.



CHAPTER 6. TABLE OF CONTENTS PART 4

- 1. Cell survival curves
 - A. linear-quadratic model
 - B. single-hit single-target model
 - C. multi-target-single hit model
 - D. The α/β ratio
- 2. Dose response curves
- 3. Normal and tumor cells: Therapeutic ratio
- 4. Relative biological effectiveness (RBE)
- 5. Oxygen effect
- 6. Dose rate and fractionation
- 7. Radioprotectors and radiosensitizers



6.4.4 RELATIVE BIOLOGICAL EFFECTIVENESS

Assumption: As the LET of radiation increases, the ability of the radiation to produce biological damage increases.

The Relative biological effectiveness (RBE) is defined as:

$$RBE = \frac{d_{low LET}}{d_{high LET}} = \frac{d_L}{d_H}$$

Isoeffective doses for the reference:

•Historically, 250 kVp x rays were taken as standard radiation.

•Today cobalt-60 gamma rays are recommended for this purpose.



In particular, the **RBE** of a radiation is defined as the **ratio of the dose required to produce the same biological effect (reduction in cell survival)** as a reference low LET radiation.



6.4.4 RELATIVE BIOLOGICAL EFFECTIVENESS

An increase in the RBE in itself offers no therapeutic advantage unless there is a differential effect making the RBE for normal tissue smaller than that for the tumor

The RBE varies with:

- Type of radiation (high or low LET).
- Type of cell or tissue (radiosensitive or radioresistant).
- Dose.
- Dose rate.
- Oxygenation -> oxygen enhancement ratio (OER)
- Fractionation.
- Cell cycle phase
- Tissue/Tumor Type



Radiation Effect and Dose Delivery

For low LET radiation, \Rightarrow RBE \propto LET, for higher LET the RBE increases to a maximum, the subsequent drop is caused by the **overkill effect**.



These high energies are sufficient to kill more cells than actually available! Causes more DNA damage than is needed so energy is wasted.

NPRE 441, Principles of Radiation Protection, Spring 2021

CHAPTER 6. TABLE OF CONTENTS PART 4

1. Cell survival curves

- A. linear-quadratic model
- B. single-hit single-target model
- C. multi-target-single hit model
- D. The α/β ratio
- 2. Dose response curves
- 3. Normal and tumor cells: Therapeutic ratio
- 4. Relative biological effectiveness (RBE)
- 5. Oxygen effect
- 6. Dose rate and fractionation
- 7. Radioprotectors and radiosensitizers



Radiation effects may be influenced especially by the presence/absence of oxygen.

The **free radicals** (**R**) produced as a result of direct or indirect effects are **very reactive** and seek to interact with other molecules which can share/donate electrons.

Molecular oxygen (O_2) has 2 unpaired electrons and readily reacts with free radicals, causing an increased likelihood that deoxyribonucleic acid (**DNA**) will be **damaged by indirect process**.

Important reactions via which oxygen can increase biological damage are: $R^{\bullet} + O_2 \rightarrow RO_2^{\bullet} \text{ (highly toxic)}$ $H^{\bullet} + O_2 \rightarrow HO_2^{\bullet}$ $HO_2^{\bullet} + HO_2^{\bullet} = H_2O_2 \text{ (highly toxic)} + O_2$

oxygen enhancement ratio (OER) to achieve equivalent biological effect





Oxygen effect is quite dramatic for low LET (sparsely ionizing) radiation, while for high LET (densely ionizing) radiation it is much less pronounced.



30 nm

Solid survival curves are for hypoxic cells; dashed survival curves are for well oxygenated cells.



□ The OER decreases as the LET increases and approaches OER = 1 at LET \approx 150 keV/µm.





•The vascular network that develops in tumors is **structurally abnormal**

- •Vessels are dilated, tortuous, elongated, with blind ends
- The abnormal vasculature results in spatial and temporal heterogeneity in blood flow that in turn produce regions of temporary or acute hypoxia, and nutrient depletion





Cells at the periphery of tumour cords growing around blood vessels become chronically hypoxic because of the consumption of most of the oxygen near the blood vessel.



Limited O2 diffusion due to high cell oxygen consumption and/or irregular vascular geometry

Reoxygenation is process by which cells that are hypoxic become oxygenated after irradiation through the killing and removal of oxic radiosensitive cells from the tumor.



radiobiologically relevant hypoxia happens at **100 μm distance from a blood vessel**



CHAPTER 6. TABLE OF CONTENTS PART 4

- 1. Cell survival curves
 - A. linear-quadratic model
 - B. single-hit single-target model
 - C. multi-target-single hit model
 - D. The α/β ratio
- 2. Dose response curves
- 3. Normal and tumor cells: Therapeutic ratio
- 4. Relative biological effectiveness (RBE)
- 5. Oxygen effect
- 6. Dose rate and fractionation
- 7. Radioprotectors and radiosensitizers



6.4.5 DOSE RATE AND FRACTIONATION

The dose delivered in radiation therapy is usually divided or "fractionated" over a treatment course lasting multiple weeks (2 Gy dose/fraction over 6 weeks). Fractionation in the context of radiotherapy is the process of dividing a dose of radiation into multiple "fractions". This practice seeks to maximize the destruction of malignant cells while minimizing damage to healthy tissues \rightarrow improve the therapeutic ratio To achieve the desired level of biological damage the total dose in a fractionated treatment must be much larger than that in a single treatment.





6.4.5 DOSE RATE AND FRACTIONATION

Conventional fractionation is explained as follows:

- Division of dose into multiple fractions allows for: (1) repair of sublethal damage between dose fractions and
 (2) repopulation of cells.
- Repair of sublethal damage is greater for late responding (healthy) tissues, while cancer cells struggle to repair their (unstable) DNA
- The repopulation of cells is greater for early responding tissues (tumors).
- Fractionation increases tumor damage through reoxygenation and redistribution of tumor cells.

Large dose/fraction more toxic to tissues with low α/β ratio compared to tissues with high α/β ratio



6.2 IRRADIATION OF CELLS

Radiosensitivity differs throughout the cell cycle with, in general:

- late S phase being the most radioresistant
- G₂/M being the most radiosensitive (Cells going through the division phase)
- G₁ phase taking an intermediate position





- The greater proportion of DNA enzymatic repair during late S phase may explain the resistance of late S phase cells
- Poor repair competence (reduced enzyme access due to chromatin compaction) explains the high radiosensitivity in G₂/M phase
- Resting cells in G₀, not involved in the cell cycle, are more resistant to radiation when compared to late S-phase cells



6.4.5 DOSE RATE AND FRACTIONATION

The **basic equation of the LQ model** describes the shape of the cell survival curves and has a biophysical origin. Cell survival after delivery of an acute dose *d* is given is:

$$S = \exp\left(-\alpha d - \beta d^2\right)$$

with α (Gy⁻¹) and β (Gy⁻²) being the linear and quadratic sensitivity coefficients

If the treatment is repeated in **N** spaced fractions, the net survival is S_N :

$$S_N = S^N = \exp\left(-N\alpha d - N\beta d^2\right)$$

$$\frac{\ln S_N}{\alpha} = -Nd - \frac{Nd^2}{(\alpha / \beta)} \implies BED = nd \left[1 + \frac{d}{\alpha / \beta} \right] = \frac{Biologically Effective}{Dose}$$



BED vs EQD2 (Equivalent dose at 2 Gy)

$$EQD_2 = D \cdot \frac{d + \alpha/\beta}{2 + \alpha/\beta} \quad EQD_2 = \frac{BED}{1 + \frac{2}{\alpha/\beta}}$$

EQD2 is calculated as derived from the linear-quadratic model D = total dose, d = dose per fraction, α = linear (first-order dose-dependent) component of cell killing, β = quadratic (second-order dose dependent) component of cell killing

CHAPTER 6. TABLE OF CONTENTS PART 4



6.4.5 DOSE RATE AND FRACTIONATION

- Basis of fractionation is rooted in 5 primary biological factors called the five Rs of radiobiology:
 - Radiosensitivity. Eukaryotic cells have different radio-sensitivities (see next slide). Tumor cells have inherent, and variable, radiosensitivity.
 - Redistribution: cells that survive a dose of radiation since in resistant phases of the division cycle, redistribute into more sensitive phases of the cell cycle during subsequent doses of radiation.
 - Repair. Healthy eukaryotic cells repair radiation damage easier than cancer cells due to their (unstable) DNA
 - Repopulation. Cells repopulate while receiving fractionated doses of radiation (visible in the shoulders).
 - Reoxygenation of hypoxic cells occurs during a fractionated course of treatment, making them more oxygenated and therefore radiosensitive to subsequent doses of radiation (the tumor cluster is "peeled" like an onion by removing the tumor layers that are oxic).



Mechanism of Causing Effects on Human Body

Radiosensitivity of Organs and Tissues

Active cell division High sensitivity

Hematopoietic system: Bone marrow and lymphatic tissues (spleen, thymus gland, lymph node)

Reproductive system: Testis and ovary

Gastrointestinal system: Mucous membrane and small-intestinal villus

Epidermis and eyes: Hair follicle, sweat gland, skin and lens

Other: Lung, kidney, liver and thyroid gland

Support system: muscle, cartilage and bone

Transmission system: nerve, brain

No cell division Low sensitivity

CHAPTER 6. TABLE OF CONTENTS PART 4

- 1. Cell survival curves
 - A. linear-quadratic model
 - B. single-hit single-target model
 - C. multi-target-single hit model
 - D. The α/β ratio
- 2. Dose response curves
- 3. Normal and tumor cells: Therapeutic ratio
- 4. Relative biological effectiveness (RBE)
- 5. Oxygen effect
- 6. Dose rate and fractionation
- 7. Radioprotectors and radiosensitizers



6.4.6 RADIOPROTECTORS AND RADIOSENSITIZERS

- Some chemical agents may alter the cell response to ionizing radiation, either reducing or enhancing the cell response:
 - Chemical agents that <u>reduce cell response</u> to radiation are called radioprotectors. They generally influence the indirect effects of radiation by scavenging the production of free radicals.
 - Chemical agents <u>that enhance cell response</u> to radiation are called <u>radiosensitizers</u>. They generally promote both the direct and indirect effects of radiation and OER.
 - **Oxygen** is a powerful oxidizing agent and therefore acts as a radiosensitizer if it is present at the time of irradiation



6.4.6 RADIOPROTECTORS AND RADIOSENSITIZERS



- Dale RG, Jones B. (Eds) Radiobiological Modelling in Radiation Oncology, The British Institute of Radiology, London (2007).
- Hall EJ, Giacca AJ. Radiobiology for the Radiologist, 6th edn, Lippincott, Williams and Wilkins, Philadelphia, PA (2006).
- ICRU INTERNATIONAL COMMISSION ON RADIATION UNITS, Absorbeddose Specification in Nuclear Medicine, Rep. 67, Nuclear Technology Publishing, Ashford, United Kingdom (2002).
- Meredith R, Wessels B, Knox S. Risks to normal tissue from radionuclide therapy, Semin. Nucl. Med. 38 (2008) 347–357.



- HALL, E., GIACCIA, A.J., Radiobiology for the Radiologist, 6th edn, Lippincott Wilkins & Williams, Philadelphia, USA (2006)
- INTERNATIONAL ATOMIC ENERGY AGENCY, Radiation Oncology Physics: A Handbook for Teachers and Students, IAEA, Vienna (2005). <u>http://www-naweb.iaea.org/nahu/dmrp/publication.asp</u>
- INTERNATIONAL ATOMIC ENERGY AGENCY, Radiation Biology: A Handbook for Teachers and Students, Training Course Series, 42, IAEA, Vienna (2010). <u>http://www-</u> pub.iaea.org/MTCD/publications/PDF/TCS-42_web.pdf
- INTERNATIONAL ATOMIC ENERGY AGENCY, Radiobiology modules in the "Applied Sciences of Oncology" distance learning course. Available on CD Contact: <u>J.Wondergem@iaea.org</u>, or downloadable for free from the IAEA website:

http://www.iaea.org/NewsCenter/News/2010/aso.html



- INTERNATIONAL COMMISSION ON RADIOLOGICAL PROTECTION, Pregnancy and Medical Radiation ICRP Publication 84, Pergamon Press, Oxford and New York (2000)
- INTERNATIONAL COMMISSION ON RADIOLOGICAL PROTECTION, Recommendations of the ICRP, ICRP Publication 103, Annals of the ICRP Volume 37/2-4, Elsevier (2008). via <u>www.sciencedirect.com</u>
- JOINER, M.C., VAN DER KOGEL, A.J., (Eds), Basic Clinical Radiobiology, 4th edn., Hodder Arnold, London, UK, (2009)
- KOENIG, T.R., WOLFF, D., METTLER, F.A., WAGNER, L.K., Skin injuries from fluoroscopically guided procedures: part 1, characteristics of radiation injury, AJR Am J Roentgenol 177 1 (2001) 3-11



- NATIONAL RESEARCH COUNCIL OF THE NATIONAL ACADEMIES, Health risks from exposure to low levels of ionizing radiation; BEIR VII phase 2, Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation, National Academies Press, Washington, DC (2006). <u>http://www.nap.edu/openbook.php?isbn=030909156X</u>
- TANNOCK, HILL, BRISTOW, HARRINGTON, (Eds), The Basic Science of Oncology, Chapters 14 & 15, 4th edn., McGraw Hill, Philadelphia, (2005)
- WAGNER, L.K., EIFEL, P.J., GEISE, R.A., Potential biological effects following high X-ray dose interventional procedures, J Vasc Interv Radiol 5 1 (1994)

